Palonosetron vs. Ondansetron for Postoperative Nausea and Vomiting in Bariatric Surgery

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

August 15, 2020

Primary Completion Date

December 15, 2020

Study Completion Date

January 1, 2021

Conditions
Nausea, PostoperativeVomiting, PostoperativePatient Reported OutcomesPain, PostoperativeAntiemetics
Interventions
PROCEDURE

Laparoscopic sleeve gastrectomy

Sleeve gastrectomy, also called a vertical sleeve gastrectomy, is a surgical weight-loss procedure. This procedure is typically performed laparoscopically, which involves inserting small instruments through multiple small incisions in the upper abdomen. During sleeve gastrectomy, about 80 percent of the stomach is removed, leaving a tube-shaped stomach about the size and shape

DRUG

Palonosetron 1mcg/kg

Injectable Palonosetron 1 mcg/kg diluted up to 5 mL with normal saline solution and injected intravenously at the end of the bariatric surgery.

DRUG

Ondansetron 1 mg/kg, max dose 8 mg

Injectable ondansetron 0.1 mg/kg, maximum of 8 mg was injected intravenously at the end of the bariatric surgery.

Trial Locations (2)

Unknown

Bagcılar Training and Research Hospital, Istanbul

Surp Pırgic Armenian Hospital, Istanbul

All Listed Sponsors
lead

Bagcilar Training and Research Hospital

OTHER_GOV

NCT04533867 - Palonosetron vs. Ondansetron for Postoperative Nausea and Vomiting in Bariatric Surgery | Biotech Hunter | Biotech Hunter